These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 27081758)

  • 1. Mouse interleukin-12/FasTI: A novel bi-functional fusion protein for cancer immuno/gene therapy.
    Yang X; Tietje AH; Yu X; Wei Y
    Int J Oncol; 2016 Jun; 48(6):2381-6. PubMed ID: 27081758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor cells expressing a fusion protein of MULT1 and Fas are rejected in vivo by apoptosis and NK cell activation.
    Kotturi HS; Li J; Branham-O'Connor M; Stickel SL; Yu X; Wagner TE; Wei Y
    Gene Ther; 2008 Oct; 15(19):1302-10. PubMed ID: 18463688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MULT1E/mIL-12: a novel bifunctional protein for natural killer cell activation.
    Tietje A; Li J; Yu X; Wei Y
    Gene Ther; 2014 May; 21(5):468-75. PubMed ID: 24572784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lentiviral delivery of novel fusion protein IL12/FasTI for cancer immune/gene therapy.
    Yang X; Yu X; Wei Y
    PLoS One; 2018; 13(7):e0201100. PubMed ID: 30044833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An IL-12/Shh-C domain fusion protein-based IL-12 autocrine loop for sustained natural killer cell activation.
    Zhu L; Zhao Z; Wei Y; Marcotte W; Wagner TE; Yu X
    Int J Oncol; 2012 Aug; 41(2):661-9. PubMed ID: 22581115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo delivery of novel anticancer fusion protein MULT1E/FasTI via adenoviral vectors.
    Kotturi HS; Li J; Branham-O'Connor M; Yu X; Wagner TE; Wei Y
    Cancer Gene Ther; 2010 Mar; 17(3):164-70. PubMed ID: 19816522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Independent contributions of GR-1+ leukocytes and Fas/FasL interactions to induce apoptosis following interleukin-12 gene therapy in a metastatic model of prostate cancer.
    Sanford MA; Yan Y; Canfield SE; Hassan W; Selleck WA; Atkinson G; Chen SH; Hall SJ
    Hum Gene Ther; 2001 Aug; 12(12):1485-98. PubMed ID: 11506692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.
    Hall SJ; Canfield SE; Yan Y; Hassen W; Selleck WA; Chen SH
    Gene Ther; 2002 Apr; 9(8):511-7. PubMed ID: 11948376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene therapy of anaplastic thyroid carcinoma with a single-chain interleukin-12 fusion protein.
    Shi Y; Parhar RS; Zou M; Baitei E; Kessie G; Farid NR; Alzahrani A; Al-Mohanna FA
    Hum Gene Ther; 2003 Dec; 14(18):1741-51. PubMed ID: 14670125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Novel Fusion Protein Melittin-MIL-2 Exhibits Strong Antitumor Immune Effect in Lung Adenocarcinoma Cell A549.
    Gao W; Li W; Wang Z; Li Y; Liu M
    Clin Respir J; 2024 Jul; 18(7):e13805. PubMed ID: 39003635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model.
    Hess SD; Egilmez NK; Shiroko J; Bankert RB
    Cancer Gene Ther; 2001 May; 8(5):371-7. PubMed ID: 11477457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural killer cell-mediated rejection of experimental human lung cancer by genetic overexpression of major histocompatibility complex class I chain-related gene A.
    Busche A; Goldmann T; Naumann U; Steinle A; Brandau S
    Hum Gene Ther; 2006 Feb; 17(2):135-46. PubMed ID: 16454647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
    Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
    Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.
    Imboden M; Murphy KR; Rakhmilevich AL; Neal ZC; Xiang R; Reisfeld RA; Gillies SD; Sondel PM
    Cancer Res; 2001 Feb; 61(4):1500-7. PubMed ID: 11245457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells.
    Lafleur EA; Jia SF; Worth LL; Zhou Z; Owen-Schaub LB; Kleinerman ES
    Cancer Res; 2001 May; 61(10):4066-71. PubMed ID: 11358827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
    Stagg J; Wu JH; Bouganim N; Galipeau J
    Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
    Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
    J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells.
    Sayers TJ; Brooks AD; Lee JK; Fenton RG; Komschlies KL; Wigginton JM; Winkler-Pickett R; Wiltrout RH
    J Immunol; 1998 Oct; 161(8):3957-65. PubMed ID: 9780164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fas-Fas ligand signaling pathway mediates an interleukin-12-induced rejection of a murine prostate tumor system.
    Zhang S; Zeng G; Kao C; Gardner T; Sweeney C; Yang NS; Eble JN; Cheng L
    Prostate; 2002 Sep; 53(1):69-76. PubMed ID: 12210482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
    Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
    Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.